DARE Bioscience reports Q3 cash $23.1M; Sildenafil Cream on track for Dec launch via 503B

Dare Bioscience, Inc.

2025-Q3 EPS reported -$1.18 revenue$6,517

Cash and equivalents $23.1M; working capital $3.8M as of Sep 30, 2025.
R&D expense $1.2M (down 56% YoY) due to grant funding; G&A $2.5M (up 25% YoY) on commercial readiness.
DARE to PLAY Sildenafil Cream on track for initial Rx fulfillment Dec 2025 via 503B compounding (near-term revenue).
Positive DSMB recommendation for Ovaprene Phase 3 study; enrollment continues.
Received $6M (Jul) and $4M (Oct) grant installments for DARE-LARC1; $3.6M expected for DARE-NHC in Nov 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.